Yahoo! Finance: Biotechnology Industry News: Positive Results Presented from Proof-of-Concept Phase II Clinical Trial of Incyte’s Oral JAK1 Inhibitor in Patients with Chronic Plaque Psoriasis

Yahoo! Finance: Biotechnology Industry News The latest news on the Biotechnology industry from Yahoo! Finance

TypePad Has the Tools Looking for a premiere blogging service? Start your blog today on TypePad. From our sponsors

Positive Results Presented from Proof-of-Concept Phase II Clinical Trial of Incyte's Oral JAK1 Inhibitor in Patients with Chronic Plaque Psoriasis Oct 3rd 2013, 06:00 [Business Wire] - Incyte Corporation announced results from a 28-day, placebo-controlled, dose-escalation Phase II proof-of-concept clinical trial involving 50 patients with chronic plaque psoriasis for its proprietary oral JAK1 inhibitor, INCB39110.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions